Nattokinase and atherosclerosis
What 2 graded rows on nattokinase agree on for atherosclerosis, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Nattokinase page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Nattokinase page, with its PubMed record.
Your question
Nattokinase and atherosclerosis
2 rows · 1,327 peopleSplit. 1 row found an improvement and 1 found no difference.
- DGrade D× 1
- ∅No effect× 1
- Rows
- 2
- Trials
- 2
- People
- 1,327
Where they differ
From the rowsThe best-graded row, grade D, is an open-label trial of 1,062 people (2022) and found an improvement. 1 row is graded No effect, our grade for adequately powered trials that found no effect.
The row that found an improvement was larger: 1,062 people, against 265 people for the row that found no difference.
The row that found no difference ran longer (3 years) than the row that found an improvement (12 months).
The row that found an improvement is newer (2022) than the row that found no difference (2021).
The rows
1 improved · 1 no difference- DGrade DCarotid plaque and lipids at high dose · Improved
Open-label trial · n 1,062 · 2022 · Adults with atherosclerosis or hyperlipidemia (China)
10,800 FU/day (3,600 FU/day also tested) · 12 months
Carotid intima-media thickness, plaque size and lipids improved at 10,800 FU/day, but 3,600 FU/day was ineffective. No noticeable adverse effects were recorded.
Row on the Nattokinase page · PubMed 36072877 (opens PubMed)
- ∅No effectCarotid atherosclerosis progression, blood pressure and clotting markers · No difference
RCT · n 265 · 2021 · Adults (median age 65) without cardiovascular disease (US)
2,000 FU/day · Median 3 years
Annual change in carotid intima-media thickness and arterial stiffness did not differ from placebo, and there was no effect on blood pressure or any laboratory measure, including coagulation and fibrinolysis factors.
Row on the Nattokinase page · PubMed 33843667 (opens PubMed)